Next Generation Vaccine™ is committed to providing cutting-edge vaccines to safeguard public health. With our state-of-the-art research facilities, superior technology and dedicated team of scientists, we strive to develop innovative solutions to combat cancer malignancies and infectious diseases.
Dr. Arabpour has M.Sc. in medical virology and Ph.D. in Biomedicine. He has a long career +12 years in vaccine discovery and evaluation in industry and academic. Designed, created, and evaluated the first Mucosal vaccine. Leading the scientific strategy and drug development, he has extensive experience in the pharmaceutical industry and leads our company with vision and expertise.
Ms. Torkzadeh with M.Sc. in Biotechnology and more than 5 years of experience in vaccine evaluation in infectious diseases. Leading the scientific strategy, she oversees our research and development efforts, driving innovation and excellence in vaccine technology.
Our proprietary and IP protected vaccine platform platform technology is versatile with great applications for cancer and infectious diseases. Our vaccine technology consists of several modules with specialized functions, working as an immune enhancer boosting the immune system against specific targets. Augmented immunity could then destroy cancer malignancy and protect against infectious diseases.
Our groundbreaking research has been published in leading scientific journals. Stay updated with our latest publications:
If you have any questions or inquiries, please feel free to contact us:
Email: marabpour@nextgenvax.com
Phone: +47-45912785